访13-ICML大会主席Franco Cavalli教授

　　F. Cavalli主席在被问及对于本届ICML大会的印象时说，“这次大会对于我们来说是非常重要的一次会议，因为有来自东方国家的积极参与。中国首次位列投送摘要前十的国家，实际上中国是仅次于美国、德国、法国和意大利之后，位居第五。”

　　“这次会议的标志是较过去我们有了更多的基础和转化性研究，成功地将基础与临床研究结合起来，并保证了实验室与临床工作人员之间持续不断的信息交流。我个人认为大会的成功之处就是将基础与临床二个完全不同的的领域完美的结合起来。”

　　This meeting is the most important event that we have had. We have very important participation from the Far East. For the first time， China is in the top ten countries that have sent us abstracts. In fact， China was in fifth place after the United States， Germany， France and Italy. I think the hallmark of this meeting has been the fact that we have much more basic and translational science than in the past and we have succeeded in integrating basic and clinical research in the same sessions and making sure there is a continuous exchange of information between people working in the laboratory and those working with patients. The integration of these two different fields is the key to the success of the conference in my opinion.

　　大会亮点

　　Cavalli主席认为本届大会有以下三个热议话题：

　　第一个主题是病毒性疾病在淋巴瘤发病机制方面的重要性正日益增强，这对理解淋巴瘤的生物学非常有帮助，并开启了新的治疗方向。

　　第二个主题是根据微小残留灶（MRD）检测指导淋巴瘤治疗的重要性不断增加。PET检查有助于指导个体化治疗，避免过度治疗或治疗不足。当然也存在争论，是否应将PET指导治疗作为标准治疗，但至少对一部分非霍奇金淋巴瘤以及霍奇金淋巴瘤应该是适用的。

　　第三个主题是淋巴瘤治疗的新药。现在有很多新药已经拿到了临床数据，并进入I期试验，结果显示一些新药非常有前景，已经证实的是节点抑制剂的优异结果（主要是霍奇金淋巴瘤，其它类型淋巴瘤的结果也正在增加）；一些新的小分子和新的免疫细胞毒抗体治疗不同类型的淋巴瘤（霍奇金淋巴瘤和T细胞淋巴瘤）。

　　There have been three main topics. The first is the increasing importance of viral diseases as an important part of the pathogenesis of lymphomas， helping us to understand the biology of lymphomas and opening up new therapeutic avenues. The second topic has been the increasing importance of using PET-adapted therapy. PET is helping us to individualize treatment and helping us to avoid overtreating as well as undertreatment. It was also shown here in a controversial debate， PET-based therapy has to be considered as standard of care， at least in some lymphomas and certainly in the treatment of Hodgkin’s lymphoma. The third group of topics is related to new drugs. We have many new drugs with clinical data that will now move to phase I trials. We already have some very interesting new drugs in phase I trials and have had confirmation of somewhat spectacular results with the checkpoint inhibitors (mainly in Hodgkin’s lymphoma but increasingly also in other subtypes)， the new small molecules and the new combined immuno-cytotoxic antibodies in the treatment of different lymphomas (Hodgkin’s as well as T-cell lymphomas). So these three topics， the importance of viral diseases， PET-adapted therapy and the new drugs， are the hot topics of this conference.